


Global Respiratory  
Syncytial Virus Vaccine  
(RSV) and Antibody  
Pipeline Market: Analysis  
By End User, By Type, By  
Region, Size and Trends  
with Impact of COVID-19  
and Forecast up to 2028

April 2022



# Global Respiratory Syncytial Virus Vaccine And Antibody Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact Of COVID 19

Dynamics

Competitive Landscape

Company Profiling

# Global Respiratory Syncytial Virus Vaccine And Antibody Market: Coverage

## Scope of the Report

Attributes	Details
Title	Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2028
Coverage	Global and Regional
Regional Coverage	The US, Europe and ROW
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2024-2028
Competition in the Market	Highly Concentrated
Key Players	Johnson & Johnson Inc., Pfizer Inc., GlaxoSmithKline, AstraZeneca Plc., Merck & Co. Inc., Sanofi, Bavarian Nordic, Moderna Inc., Meissa Vaccines, Advaccine, and Codagenix

# Global Respiratory Syncytial Virus Vaccine And Antibody Market

## Executive Summary

RSV, or respiratory syncytial virus, is a common respiratory virus that causes mild, cold-like symptoms in both the upper and lower respiratory tracts. According to the Cleveland Clinic, RSV affects around 57,000 children under the age of five in the US each year. Despite massive global research efforts and decades of targeting RSV, there is still a significant unmet medical need. Potential therapeutics have had a difficult time proving a favorable efficacy in the past. The numbers tell the story, there are currently no FDA-approved RSV medicines for adults and only two for at-risk infants, even those have severe drawbacks. However, the RSV vaccine development has made significant progress during the past few years and the global RSV vaccine and antibody market is expected to be worth US\$2.56 billion in 2024, rising to US\$9.53 billion in 2028. The market is anticipated to grow at a CAGR of 38.9% for the period 2024-2028.


Global respiratory syncytial virus vaccine and antibody market can be classified on the basis of end user (adult and maternal & pediatric) and type (vaccine and antibody). Among the type, vaccine is projected to be the fastest growing segment, with a CAGR of 44.22% during the forecast period and among the end user, adult segment is expected to hold the largest share of approximately 60% of the market in 2024, owing to the changing demographics of the population and rising prevalence of RSV in older and immunocompromised adults.

RSV epidemiology has changed substantially as a result of the COVID-19 pandemic. The RSV season in 2020 was short or non-existent in many areas, with only a few cases. Trial recruitment had largely paused while numerous immunization protocols for COVID-19 were being developed.

Global respiratory syncytial virus vaccine and antibody market is expected to show a significant increase during the forecast period, i.e. from 2024 to 2028. The growth can be attributed to rising prevalence of RSV, rapid urbanization, increasing geriatric population, increase in healthcare expenditure, greater unmet need, growing instances of RSV among kids, and favorable government support. However, some challenges are also impeding the growth of the market such as high cost of vaccine development and inequitable access to vaccines.

# Respiratory Syncytial Virus Vaccine And Antibody Market: Global Analysis


## Global Respiratory Syncytial Virus Vaccine And Antibody Market by Value



Global respiratory syncytial virus vaccine and antibody market is expected to be worth US\$... billion in 2024 and is anticipated to reach up to US\$... billion by 2028, with a CAGR of xx%.


# Respiratory Syncytial Virus Vaccine And Antibody Market: Global Analysis

**Global Respiratory Syncytial Virus Vaccine And Antibody Market by Type; 2024 & 2028**



Type	Share (2024)	Share (2028)
RSV Vaccine	xx%	xx%
RSV Antibody	xx%	xx%


**Global Respiratory Syncytial Virus Vaccine And Antibody Market by End User; 2024 & 2028**



End User	Share (2024)	Share (2028)
Adult	xx%	xx%
Maternal & Pediatric	xx%	xx%

# Respiratory Syncytial Virus Vaccine And Antibody Market: Global Analysis

## Global Respiratory Syncytial Virus Vaccine And Antibody Market by Region; 2024




The US, xx%

Europe, xx%


ROW, xx%

# Respiratory Syncytial Virus Vaccine And Antibody Market: End User Analysis

## Global Adult Respiratory Syncytial Virus Vaccine And Antibody Market by Value




## Global Maternal & Pediatric Respiratory Syncytial Virus Vaccine And Antibody Market by Value




End User	CAGR (2024-2028)
Adult	xx%
Maternal & Pediatric	xx%

# Respiratory Syncytial Virus Vaccine And Antibody Market: Type Analysis

Global Respiratory Syncytial Virus Vaccine Market by Value




Global Respiratory Syncytial Virus Vaccine Market by End User, 2024



Type	CAGR (2024-2028)
Adult Vaccine	xx%
Maternal & Pediatric Vaccine	xx%


# Respiratory Syncytial Virus Vaccine And Antibody Market: Type Analysis

Global Respiratory Syncytial Virus Vaccine Market by Region, 2024




# Respiratory Syncytial Virus Vaccine And Antibody Market: Type Analysis

Global Respiratory Syncytial Virus Antibody Market by Value




Global Respiratory Syncytial Virus Antibody Market by Region, 2024




# Respiratory Syncytial Virus Vaccine And Antibody Market: Regional Analysis

## The US Respiratory Syncytial Virus Vaccine And Antibody Market by Value




## Europe Respiratory Syncytial Virus Vaccine And Antibody Market by Value




Region	CAGR (2024-2028)
The US	xx%
Europe	xx%
ROW	xx%

# The US Respiratory Syncytial Virus Vaccine And Antibody Market: An Analysis

The US Respiratory Syncytial Virus Vaccine Market by Value




The US Respiratory Syncytial Virus Antibody Market by Value




Type	CAGR (2024-2028)
RSV Vaccine	xx%
RSV Antibody	xx%

# The US Respiratory Syncytial Virus Vaccine And Antibody Market: An Analysis

## The US Adult Respiratory Syncytial Virus Vaccine Market by Product Type




## The US Respiratory Syncytial Virus Antibody Market by Product Type




Adult RSV Vaccine Candidates	RSV Antibody Candidates	CAGR (2024-2028)
GSK3844766A	Synagis	xx%
RSVMVA-BN	Nirsevimab	xx%
Bars13	MK-1654	xx%
CodaVax		xx%
mRNA-1345		xx%

# Europe Respiratory Syncytial Virus Vaccine And Antibody Market: An Analysis

Europe Respiratory Syncytial Virus Vaccine Market by Value




Europe Respiratory Syncytial Virus Antibody Market by Value



Type	CAGR (2024-2028)
RSV Vaccine	xx%
RSV Antibody	xx%

# Global Respiratory Syncytial Virus Vaccine And Antibody Market: Dynamics



# Global Respiratory Syncytial Virus Vaccine And Antibody Market: Competitive Landscape

## Players Profiled

- Johnson & Johnson Inc.
- Pfizer Inc.
- GlaxoSmithKline
- AstraZeneca Plc.
- Merck & Co. Inc.
- Sanofi
- Bavarian Nordic
- Moderna Inc.
- Meissa Vaccines
- Advaccine
- Codagenix